PT  - JOURNAL ARTICLE
AU  - Buckley, Rita
TI  - No Significant Difference in Treatment versus Supportive Care in Stage IV NSCLC
DP  - 2014 Jul 01
TA  - MD Conference Express
PG  - 10--11
VI  - 14
IP  - 3
4099  - http://mdc.sagepub.com/content/14/3/10.short
4100  - http://mdc.sagepub.com/content/14/3/10.full
AB  - Researchers in Egypt conducting a prospective, Phase 3, randomized trial found no significant difference in time to progression or overall survival in patients with stage IV advanced and metastatic non—small cell lung cancer (NSCLC) who received either gemcitabine or best supportive care after induction therapy. Findings were displayed in a poster presentation.